



## Relationships between serum lipid profile and HbA1c levels in patients with diabetes

Habibeh Sadat Mosavi <sup>1</sup> , Mohammad Taher Hojjati <sup>1\*</sup> , Khodabardi Kalavi <sup>1</sup>

1. Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran

\* Correspondence: Mohammad Taher Hojjati. Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran. Tel: +989113562819;

Email: [mthhematology@gmail.com](mailto:mthhematology@gmail.com)

### Abstract

**Background:** Diabetes mellitus (DM) is a metabolic disease characterized by hyperglycemia, disturbed lipid metabolism, and cardiovascular disease (CVD). Poor glycemic control results in lipid and lipoprotein abnormalities, suggesting that dyslipidemia is secondary to insulin resistance or factors closely related to insulin resistance. Glaciated hemoglobin (HbA1c) is a routinely used marker for long-term glycemic control. This form of hemoglobin is chemically processed through post-translational glycosylation that reflects the plasma glucose concentration during the last two to three months.

**Methods:** This cross-sectional study was conducted on blood samples from 592 cases referred to Dezyani Specialty Clinic, affiliated with the Golestan University of Medical Sciences. In patients with diabetes mellitus (DM) and non-diabetic individuals, hemoglobin A1c (HbA1c), total cholesterol (T-chol), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured.

**Results:** In the study, there were 460 female participants (76.9%) and 132 male participants (23.1%). Among them, 403 (67.4%) were diabetic patients, and 193 (32.4%) were non-diabetic. HbA1c levels were significantly lower in younger individuals than in middle-aged participants ( $p=0.000$ ). No significant difference was found between middle-aged and older individuals ( $p>0.121$ ). LDL levels were significantly lower in the young group than in the middle-aged group ( $p<0.001$ ). Total cholesterol (TC) was also significantly lower in the young group compared to middle-aged and older groups ( $p<0.001$ ).

**Conclusion:** HbA1c can be a helpful lipid and glycemic control marker in diabetes.

### Article History

Received: 1 January 2024

Received in revised form: 29 April 2024

Accepted: 9 September 2024

Published online: 16 October 2024

DOI: [10.29252/mlj.18.5.28](https://doi.org/10.29252/mlj.18.5.28)

### Keywords

Glycated hemoglobin

Lipids

Diabetes mellitus

Article Type: Original Article



OPEN ACCESS



© The author(s)

### Introduction

Diabetes mellitus (DM) is a metabolic disease characterized by hyperglycemia, disturbed lipid metabolism, and cardiovascular disease (CVD). It develops when insufficient insulin is produced or when the available insulin does not function correctly. In both types of diabetes (Types 1 and 2), hyperglycemia is commonly associated with hyperlipidemia, which is usually defined by marked elevation of LDL-C, Total Cholesterol (T-chol), and TG and low levels of HDL-C (1).

Approximately 100 million people worldwide are estimated to have diabetes mellitus, and the incidence of diabetes is increasing. Diabetes leads to an increase in body fat due to decreased insulin levels, insulin resistance, and the accumulation of toxic substances in the body (2). Diabetes mellitus is responsible for approximately 5% of all deaths globally on an annual basis. This is due to the fact that chronic hyperglycemia is associated with long-term complications and morbidities and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels due to micro- and macro-vascular complications (3).

Obesity, hypertension, aging, smoking, and a sedentary lifestyle are as known CVD risk factors. Patients with diabetes, especially those with Type 2 diabetes mellitus (T2DM), face increased morbidity and mortality, as they are at a greater risk of cardiovascular death compared to non-diabetic individuals. Patients with T2DM often have an atherogenic lipid profile characterized by high plasma levels of triglyceride (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) but low levels of high-density lipoprotein cholesterol (HDL-C) (4,5).

Poor glycemic control results in lipid and lipoprotein abnormalities, suggesting dyslipidemia may be secondary to insulin resistance or factors closely related to insulin resistance (6). This may be due to increased free fatty acid secondary to insulin resistance and increased proinflammatory cytokines from enlarged adipose tissue (7). The combination of hyperglycemia and dyslipidemia produces an atherogenic environment within the circulation, accelerating the progression to atherosclerosis (8).

Glaciated hemoglobin (HbA1c) is a routine marker for long-term glycemic control. This type of hemoglobin, which is the product of a chemical process called post-translational glycosylation and reflects the amount of plasma glucose concentration during the preceding two to three months, is used for monitoring glycemic control in patients with diabetes (9). However, it does not reflect short-term glycemic control. There is evidence that there is a correlation between HbA1c and CV (Cardiovascular) complications in diabetic patients. In patients with diabetes, high HbA1c levels significantly increase the risk of cardiovascular disease (CVD), and numerous studies have shown a strong association between HbA1c and CVD. Therefore, it can be suggested that HbA1c may predict dyslipidemia and CVD as a biomarker.

Correlating the HbA1c levels, lipid profiles, and related risk ratios in diabetic patients would be of great assistance. This would facilitate using HbA1c as a dual marker for glycemic control and dyslipidemia in T2DM patients, thereby reducing the cost of monitoring both conditions, particularly in low-resource settings (10). Therefore, this study was designed to determine the relationship between HbA1c and lipid profile in DM patients and non-DM individuals attending the Dezyani Specialty Clinic affiliated with the Golestan University of Medical Sciences in Gorgan.

### Methods

This prospective cross-sectional descriptive study was conducted between April and August 2023, and participants were recruited from Dezyani Specialty Clinic Affiliated with Golestan University of Medical Sciences. The patients over 18 who were not pregnant, had no malignancy, were not under dialysis, and received no anti-lipid medication were included. Based on the questionnaire and HbA1C level, the patients were divided into two diabetic and non-diabetic groups. For the study, 5 ml blood samples were collected from each participant. The blood was centrifuged within one hour of collection, and the serum was transported in a suitable container. All tests were done on the same day as the blood sampling. The HbA1c levels were measured by the Dyazin kit (Iran), and all lipid profile tests were performed using the Pars Azmon kit (Iran). The data were analyzed using SPSS 21 software. The Kolmogorov-Smirnov test was conducted to assess the normal distribution of the results, while the student's t-test was employed to compare the results between the two groups.

### Results

Study participants were 460 females (76.9%) and 132 (23.1%) males; 403 (67.4%) were diabetic patients, and the other 193 (32.4%) were nondiabetic participants. The mean age in DM patients was  $52.9 \pm 11.3$ , and in the DM group, it was  $40.4 \pm 15.6$ . One hundred sixty-three (27.3%) patients were younger than 40, 307 (51.3%) were between 40 and 60, and 127 (21.4%) were older than 60 years old (Table 1).

Results of this study showed lower HbA1c levels in younger ages than middle-aged persons ( $p=0.000$ ), while the difference was not significant between the middle-aged and older individuals ( $p>0.121$ ). LDL plasma level was significantly lower in the young group than in the middle-aged group ( $p<0.001$ ), and there was no significant difference between the middle-aged and older age groups ( $p<0.285$ ). TC was significantly lower in the young age group compared to the middle and old age groups ( $p<0.001$ ). HDL-C and TG plasma levels were not significantly different among all age groups. There were no significant

differences in HDL-C plasma levels among different age groups. In contrast, regarding other parameters, there were significant differences in plasma levels in DM and non-DM groups (Table 2). Studied parameters significantly differed between female and male DM and non-DM groups, but HDL-C was not statistically significant in males (Table 3).

HbA1c level in the non-DM group was significantly correlated with plasma TG and total cholesterol levels ( $p=0.05$  &  $p=0.01$ ). At the same time, there was no significant correlation between LDL-C and LHL-C plasma levels. This

parameter had a significant inverse relationship with LDH-C plasma levels ( $p=0.05$ ) in DM patients, and no significant relationship was seen between TG and total cholesterol levels. TG plasma levels were significantly correlated with plasma LDL-C and total cholesterol levels ( $p=0.01$  in both) in the DM group without any significant relationship with HDL-C. An inverse relationship was seen between HDL-C, LDL-C, and fasting blood sugar (FBS) in the non-DM group ( $p=0.01$ ) (Table 4).

**Table 1.** Results of laboratory variables based on age in the population under study

Age range		A1c	LDLC	HDLC	TG	Cholesterol
Young	N	163	163	163	163	163
	Mean	6.577	99.64	50.18	246.83	181.10
	Std. Deviation	2.4695	31.536	17.470	784.300	58.236
Middle age	N	307	307	307	307	307
	Mean	9.016	118.02	47.99	253.43	204.09
	Std. Deviation	5.6950	68.720	28.475	246.796	49.706
Old	N	126	127	126	126	126
	Mean	8.292	111.86	52.60	222.78	200.91
	Std. Deviation	2.2659	35.936	38.285	135.251	53.068

**Table 2.** Laboratory variables result in two diabetic and non-diabetic groups

Diabetes status		Age	LDLC	HDLC	TG	Cholesterol
Non-diabetic	N	193	193	192	192	192
	Mean	40.35	89.01	52.73	99.05	160.43
	Std. Deviation	15.563	22.079	32.033	39.472	26.137
Diabetic	N	403	403	403	403	403
	Mean	52.89	122.53	48.06	314.59	214.46
	Std. Deviation	11.273	62.385	26.576	533.263	54.686
P-value		0.001	0.000	0.062	0.001	0.000

**Table3.** Analysis of investigated variables in women

Variables	Diabetes status	N	Mean	Std. Deviation	P-value
Age	Non-diabetic	158	39.23	14.604	0.001
	Diabetic	302	53.24	11.027	
LDLC	Non-diabetic	158	87.53	21.823	0.001
	Diabetic	302	121.61	69.146	
HDLC	Non-diabetic	157	53.55	33.78	0.045
	Diabetic	302	48.05	14.705	
TG	Non-diabetic	157	95.11	38.249	0.001
	Diabetic	302	328.35	604.203	
Cholesterol	Non-diabetic	157	159.86	26.568	0.001
	Diabetic	302	214.01	54.94	

**Table 4.** Analysis of investigated variables in men

Variables	Diabetes status	N	Mean	Std. Deviation	P-value
Age	Non-diabetic	35	45.43	18.723	0.21
	diabetic	100	51.86	12.035	
LDLC	Non-diabetic	35	95.71	22.298	0.001
	Diabetic	100	125.14	35.428	
HDLC	Non-diabetic	35	49.06	22.622	0.898
	Diabetic	100	47.97	47.006	
TG	Non-diabetic	35	116.74	40.569	0.001
	Diabetic	100	274.79	205.646	
Cholesterol	Non-diabetic	35	163.00	24.303	0.001
	Diabetic	100	215.86	54.442	

## Discussion

DM is characterized by hyperglycemia and disruption of carbohydrate, lipid, and protein metabolism. In this study, we investigated the association between serum lipid profile and HbA1c in DM patients and healthy individuals. 76.9% of the participants were females, and 23.1 % were males. The higher proportion of women may be attributed to the fact that women had more free time and paid more attention to their health than men in the studied region.

Most organ damage in DM patients can be attributed to complications due to hyperglycemia, which results in disturbances in fat metabolism and immune inflammatory response, such as platelet activation, due to endothelial injury (10).

It is documented that management of lipid abnormalities by early detection of serum lipid status can prevent CVD and CVA (Cardiovascular accident) in DM patients. Investigation of lipid profiles and metabolic changes in DM patients can be challenging as various parameters influence blood indicators such as diabetes duration, control, and patient's conditions such as genetic background, age, and ethnicity. In a study, DM-related CVD mortality in older individuals with diabetes was reported as 47% in those with early intervention and 54% in those with delayed intervention (11). Still, poor randomization and data collection limits the power of this study.

The association between hyperglycemia, high HbA1c plasma levels, high TC, TG, LDL-C levels, and low HDL-C levels is well-known and reported in most studies. This study investigated the association between HbA1c and lipid profiles in DM and non-DM patients. Consistent with our findings, Ghari Arab et al. reported that HbA1c levels were directly associated with lipid profiles in DM patients (12). In both groups, plasma glucose, A1C levels, TC, and LDL-C levels were lower in younger patients. In Nanaware A, and Moss et al., and Moss et al. studies, the results were similar to ours (13,14). Mahajan et al. observed that plasma HbA1c levels were associated with LDL-C, TG, TC, and VLDL-C (Very low-density lipoprotein) levels (15). Similarly, a study from Bangladesh suggested that HbA1c plasma levels could predict and prevent hyperglycemia in DM patients (16). Parsanassab et al. reported a significant correlation between HbA1c and HDL-C, LDL-C, TC, and TG. However, this was regardless of age group. This study detected no significant association between age parameters and lipid profiles, except for HbA1c and HDL-C levels, which were inversely correlated. In one study, LDL-C, TG, and TC levels were lower in DM patients with HbA1c levels lower than 7, while these levels were higher in patients with more than HbA1c levels higher than 7 (17). Despite inconsistencies among studies, HbA1c levels and related parameters may serve as helpful laboratory markers for diabetes management.

## Conclusion

In conclusion, this study's findings can enhance our understanding of the complex relationship between glycemic control and lipid metabolism in managing diabetes. Regular monitoring and early intervention could significantly improve patient outcomes and reduce the burden of diabetes-related complications. As healthcare evolves, integrating new insights into clinical practice can enhance the quality of diabetes care.

## Acknowledgement

The research presented here reflects the findings and insights gained during the author's training as a master degree of general biochemistry. The author expresses sincere gratitude to the staff and management of Dezyani Specific Clinic for their support and cooperation during the study.

## Funding sources

The study received no funding.

## Ethical statement

This research was conducted as part of a thesis at Shahrood Azad University, identified by the code 162633792.

## Conflicts of interest

The authors confirm that they have no conflicts of interest to disclose.

## Author contributions

Habibeh Sadat Mousavi: data collection and study performance; Mohammad Taher Hojjati: study design, data analysis, and manuscript writing; Khodabderdi Kalavi: study design and manuscript writing.

## References

1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract.* 2019;157:107843. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Bhowmik B, Siddiquee T, Mujumder A, Afsana F, Ahmed T, Mdala IA, et al. Serum Lipid Profile and Its Association with Diabetes and Prediabetes in a Rural Bangladeshi Population. *Int J Environ Res Public Health.* 2018;15(9):1944. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. B Aziz S, K. Mohi aldeen S, K. Chlimeran S. Evaluation of lipid profile in patients with type II diabetes mellitus on different treatment. *Tikrit J. Pharm. Sci.* 2023;9(2):253-61. [View at Publisher] [DOI] [Google Scholar]
4. Nnakenyi ID, Nnakenyi EF, Parker EJ, Uchendu NO, Anaduaka EG, Ezeanyika LU. Relationship between glycaemic control and lipid profile in type 2 diabetes mellitus patients in a low-resource setting. *PAMJ.* 2022;41(1):281. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. McGill HC Jr, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. *Circulation.* 2008;117(9):1216-27. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Ozder A. Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study. *Lipids Health Dis.* 2014;13:183. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Nassar PO, Walker CS, Salvador CS, Felipetti FA, Orrico SR, Nassar CA. Lipid profile of people with diabetes mellitus type 2 and periodontal disease. *Diabetes Res Clin Pract.* 2012;96(1):35-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The Diabetes Mellitus-Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. *Int J Mol Sci.* 2020;21(5):1835. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Sherwani SI, Khan HA, Ekzhaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. *Biomark Insights.* 2016;11:95-104. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. *Int J Vasc Med.* 2012;2012:918267. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow up from the Framingham study. *Jama.* 1987;257(16):2176-2180. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Ghari Arab A, Zahedi M, Nejad VK, Sanagoo A, Azimi M. Correlation between hemoglobin A1c and serum lipid profile in type 2 diabetic patients referred to the diabetes clinic in Gorgan Iran. *Journal of clinical and basic research.* 2018;2(1):26-31 [View at Publisher] [DOI] [Google Scholar]
13. Nanaware A, Mankeshwar A. assessment of long-term glycemic control (HbA1c) and its correlation with biochemical and other parameters in patients with type 2 diabetes mellitus in an urban community setting. *International journal of medical science and public health.* 2017;6(2):239. [View at Publisher] [DOI] [Google Scholar]
14. Moss Se, Klein R, Klein BE, Muer Sm. The association of glycemia and cause specific mortality in a diabetic population. *Archives of internal Medicine.* 1994;154(21):2473-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Mahajan R, Koley S. Association of HbA1c with lipid profiles in patients with type2 diabeted meliyus. *Int J Biomed Res.* 2016;7(3):239-43. [View at Publisher]
16. Begum A, Irfan S, Hoque M, Habib S, Parvin S, Malek R, et al. Relationship between HbA1c and lipid profile seen in Bangladeshi type 2 diabetes mellitus patients attending Birdem hospital: A cross-sectional study. *MMJ.* 2018;28(1):91-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Parsanassab H, Muradi Paudeh B, Alizadeh A, Abediankenari S. Evaluation of correlation between HbA1c with the risk factors of lipid profile in patients with type diabetes. *Journal of Maznderan university of medical sciences.* 2012;21(2):153-6. [View at Publisher] [PMID]

## How to Cite:

Mosavi HS, Hojjati MT, Kalavi Kh. Relationships between serum lipid profile and HbA1c levels in patients with diabetes. *Med Lab J.* 2024;18(5):28-30.